NYMXF
NYMOX PHARMACEUTICAL CORP
$0.12
▲ 0.00%$0.12▲ +1.87%
over 1Y
L $0.04H $0.15
Today+0.0%
1W+0.0%
1M-5.4%
3M+96.7%
YTD+157.5%
1Y+1.9%
Sell
Conviction
Horizon
Medium (3–12mo)
Mixed signals in the latest filings.
NYMOX PHARMACEUTICAL CORP shows limited reported revenue.
On these fundamentals, NYMXF screens as SELL on the SEC figures.
Is NYMXF a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 0 @ ~0.00 est
- Short put 0 @ ~0.00 est
debit $0max +$0max $0
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
No income data filed.
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$11.3M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗6-KPeriod ending 2026-06-022026-06-03open ↗6-KPeriod ending 2026-03-272026-03-27open ↗6-KPeriod ending 2025-11-072025-11-07open ↗6-KPeriod ending 2025-10-222025-10-22open ↗6-KPeriod ending 2025-10-222025-10-22open ↗6-KPeriod ending 2025-09-232025-09-23open ↗20-FPeriod ending 2024-12-312025-06-03open ↗6-KPeriod ending 2025-05-222025-05-22open ↗NT 20-FPeriod ending 2024-12-312025-05-01open ↗6-KPeriod ending 2025-03-112025-03-11open ↗6-KPeriod ending 2024-09-302025-01-02open ↗6-KPeriod ending 2024-12-172024-12-17open ↗
Frequently asked
- Is NYMOX PHARMACEUTICAL CORP (NYMXF) a buy?
- NYMXF currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
- What is NYMOX PHARMACEUTICAL CORP's quality score?
- NYMXF scores 71.7391304347826/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001018735, latest 6-K filed 2026-06-03) · EODHD · as of 7/5/2026, 9:35:09 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 5, 2026, 5:35 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.